智飞生物重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理

Core Points - The core announcement is that Zhifei Biological's subsidiary, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01 adjuvanted with CHO cells [1] Group 1 - The clinical trial application was accepted, allowing the company to proceed with trials if no objections are raised within 60 days from the acceptance date [1]